Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nanobiotix S.A. - Sponsored ADR (NBTX : NSDQ)

• Company Description    NANOBIOTIX is a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases. NANOBIOTIX is based in CAMBRIDGE, Mass. Number of Employees: 108

• Price / Volume Information    Yesterday's Closing Price: $19.87 Daily Weekly Monthly 20 Day Moving Average: 114,728 shares Shares Outstanding: 47.94 (millions) Market Capitalization: $952.63 (millions) Beta: 0.71 52 Week High: $30.35 52 Week Low: $2.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.81% -18.01% 12 Week 151.20% 140.79% Year To Date 592.34% 505.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 RUE DE WATTIGNIES - PARIS,I0 75012 FRA ph: 33-1-40-26-04-70 fax: - None http://www.nanobiotix.com

• General Corporate Information    Officers Dr. Laurent Levy - Chairman of the Executive Board and Co-founder Dr. Gary Phillips - Chairman Ms. Anne-Marie Graffin - Vice Chairwoman Mr. Bart Van Rhijn - Chief Financial and Business Officer Ms. Anne-Juliette Hermant - Chief People Officer Peer Information Nanobiotix S.A. - Sponsored ADR (CORR.) Nanobiotix S.A. - Sponsored ADR (RSPI) Nanobiotix S.A. - Sponsored ADR (CGXP) Nanobiotix S.A. - Sponsored ADR (BGEN) Nanobiotix S.A. - Sponsored ADR (GTBP) Nanobiotix S.A. - Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 63009J107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 47.94 Most Recent Split Date: (:1) Beta: 0.71 Market Capitalization: $952.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.07 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: 283.86 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - - 03/31/25 - - Current Ratio 09/30/25 - - 06/30/25 - 0.63 03/31/25 - - Quick Ratio 09/30/25 - - 06/30/25 - - 03/31/25 - - Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -1.66 03/31/25 - - Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©